Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone, or with metformin and not more than one other oral antidiabetic drug~2. Diagnosis of type 2 diabetes prior to informed consent~3. Glycosylated haemoglobin A1 (HbA1c)at screening:~   For patients undergoing wash out of previous medication: HbA1c 6.5 - 9.0% For patients not undergoing wash-out of previous medication: HbA1c 7.0 - 10.0%~4. Glycosylated haemoglobin A1 (HbA1c) 7.0 - 10.0% at the beginning of Placebo Run-in~5. Age 18 -80 years~6. BMI (Body Mass Index) less than 40 kg/m2~7. Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation~Exclusion criteria:~1. Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent~2. Impaired hepatic function~3. Known hypersensitivity or allergy to the investigational product or its excipients or metformin or placebo~4. Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent~5. Treatment with an injectable GLP-1 analogue (e.g. exenatide) within 3 months prior to informed consent~6. Treatment with insulin within 3 months prior to informed consent~7. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent~8. Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse~9. Participation in another trial with an investigational drug within 2 months prior to informed consent~10. Pre-menopausal women who:~    * are nursing or pregnant,~   * or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.~11. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.~12. Renal failure or renal impairment~13. Unstable or acute congestive heart failure~14. Acute or chronic metabolic acidosis (present in patient history)~15. Hereditary galactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Linagliptin (Type: EXPERIMENTAL): Patients receive linagliptin 5 mg tablets once daily
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo tablets matching linagliptin 5 mg tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).